LENZ Stock Forecast & Price Target

LENZ Therapeutics is attractive because VIZZ offers a differentiated once-daily, pupil-selective aceclidine therapy that has shown clinically meaningful 2-line or greater near-vision improvement in about 70% of patients for 8–10 hours with a benign safety profile, addressing a large presbyopia market of 128MM U.S. adults. The company has completed its Phase III program with positive efficacy results and a 6-month safety study, while the FDA approval on July 31st, 2025 and expected commercial availability in Q4:2025 support the start of meaningful revenue generation. Commercial traction is being reinforced by telehealth access, national TV promotion, a 94% increase in weekly mail-order scripts, and a cash position of $220.0M that management says should fund the business to positive cash flow.

LENZ Therapeutics is facing a negative fundamental setup because sales expectations for VIZZ were cut sharply to $2.5M for Q3 from $4M and to $10M for FY26 from $15M, signaling weaker-than-expected prescription momentum. The company also carries meaningful clinical, regulatory, and commercial risk, with long-term safety and efficacy of VIZZ/LNZ100 not yet comprehensively established and competition likely to pressure adoption. Even if management can improve awareness and Rx growth, sentiment remains fragile because commercialization is still early and outcomes may be affected by changing macroeconomic conditions tied to consumer discretionary spending.